← All trials
NCT05807139
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 3, 2024
- Primary completion
- Aug 31, 2024
- Completion date
- Sep 7, 2024
- First posted
- Apr 11, 2023
- Last posted
- Dec 29, 2023
- Enrollment
- 20
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute on Drug Abuse (NIDA)Lead sponsor
- National Institute on Drug Abuse (NIDA)Overall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.